I wonder what the outcome would have been had the efficacy assessment been based on mba alone. Would that constitute proof and we would be progressing rapidly to commercialisation?
If they have got fda signed off on mba as the efficacy criteria, as could be assumed from their comments, surely NEU just has to repeat the same outcome and we are in business. I am pretty optimistic.
- Forums
- ASX - By Stock
- NEU
- Ann: Neuren presents at Rettsyndrome.org 2016 Research Symposium-NEU.AX
Ann: Neuren presents at Rettsyndrome.org 2016 Research Symposium-NEU.AX, page-4
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$20.00 |
Change
0.090(0.45%) |
Mkt cap ! $2.556B |
Open | High | Low | Value | Volume |
$19.88 | $20.07 | $19.73 | $11.80M | 591.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 5901 | $19.97 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.00 | 3262 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 2596 | 19.800 |
1 | 100 | 19.750 |
1 | 250 | 19.700 |
2 | 142 | 19.500 |
1 | 550 | 19.440 |
Price($) | Vol. | No. |
---|---|---|
20.000 | 390 | 2 |
20.050 | 2000 | 1 |
20.100 | 239 | 1 |
20.140 | 962 | 1 |
20.150 | 500 | 1 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online